Answers are grounded in this paper and cite their sources.
Psoriasis is a prevalent skin disorder affecting approximately 2-3% of the population in the USA. Its complex and varied presentations necessitate a diverse range of available therapeutic options. While topical corticosteroid therapy is conventionally employed as first-line treatment, long-term usage increases the risk of adverse events, prompting the consideration of alternatives including steroid-sparing agents such as vitamin D. In this article, we review literature from topical and oral vitamin D trials for the treatment of psoriasis. Topically, vitamin D analogues have been well established as an effective long-term treatment, particularly when used in combination with other therapies. Moreover, combination therapy with immunomodulators such as apremilast and methotrexate has shown promise as well. Conversely, oral vitamin D supplementation trials have yielded more inconsistent results, with some supplementation clinical trials showing significant psoriasis resolution and others showing no significant changes in psoriasis outcome. Vitamin D deficiency status, seasonal variation and body mass index were factors that may have modulated the therapeutic effect of vitamin D supplementation. Further study combining vitamin D supplementation with pre-existing treatments may also augment the effect of monotherapy. Studies on the synergistic effects of combination therapies with oral vitamin D or the development of foam-based or microneedle drug delivery systems may be promising next steps.
No takes yet. Share an insight, caveat, or question.
Mai et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: